The findings will allow for more targeted treatment approaches.
In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
If the flu season wrapping up in Australia is any indication, the U.S. may be in for a particularly bad one.
The award-winning Multiple Sclerosis Center of Excellence at OMRF is one of the preeminent MS research and treatment centers in the world.
In MS, immune cells attack the protective covering of nerves in the brain, causing vision problems, tremors, paralysis, painful spasms, imbalance and cognitive changes.
Autoimmune diseases are conditions in which the immune system becomes unbalanced and turns on the body instead of protecting it.